Cryopreservation of paediatric ovarian tissue with an updated version of the Edinburgh criteria for appropriate patient selection. Issue 4 (April 2022)

• Record Type: Journal Article
• Authors: Takae, Seido; Furuta, Shigeyuki; Iwahataa, Hideyuki; Iwahata, Yuriko; Keino, Dai; Kanamori, Ryo; Oyama, Kei; Tanaka, Kunihide; Shiraishi, Eriko; Suzuki, Yuki; Sugishita, Yodo; Horage, Yuki; Sakamoto, Miki; Mori, Tetsuya; Kitagawa, Hiroaki; Suzuki, Nao
• Is Part Of: Reproductive biomedicine online. Volume 44:Issue 4(2022)
• Page Start: 667
• Page End: 676
• Publication Date: 2022-04
• Subjects: Cancer patient -- Fertility preservation -- Oncofertility -- Ovarian tissue cryopreservation -- Pediatric patient; Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2021.10.009
• Languages: English
• ISSNs: 1472-6483

Abstract

Highlights: Primary disease and age varied in fertility preservation children and adolescents Revised patient selection criteria appear appropriate in a short observation period OTC patient selection criteria should be revised with the development of technology Abstract: Research question: Are the revised patient selection criteria for fertility preservation of children and adolescents appropriate? Design: A retrospective and prospective observational cohort study implemented at a university hospital approved for fertility preservation by an academic society. The characteristics of children and the process of fertility preservation consultation were investigated. Mortality, the longitudinal course of the endocrine profile and the menstrual cycle were confirmed in patients who underwent ovarian tissue cryopreservation (OTC) before the age of 18 years. Results: Of the 74 children and adolescents referred for a fertility preservation consultation, 40 (54.1%) had haematological disease, which included patients with rare diseases. The mean age of patients was 11.1 ± 4.3 years (median 12 years, range 1–17 years). In accordance with the revised criteria, 31 (41.9%) patients had their ovarian tissue cryopreserved. Two out of 31 had complications after surgery (infection and drug allergy) and one patient with leukaemia (3.2%) had minimum residual disease on the extracted ovarian tissue. Of the 14 patients (>12 years) who completed treatment, 12 (85.7%) had primary ovarian insufficiency (POI) more than a year after treatment. Two out of 31 (6.5%) died because of recurrence of their underlying disease (median 28 months, range 0–60 months). Oocyte cryopreservation, as an additional and salvage fertility preservation treatment, was suggested to five patients with biochemical status POI (procedures pending). Conclusion: The primary disease and patients' ages varied in fertility preservation for children and adolescents. Our patient selection criteria might be appropriate over a short follow-up period.